| 1 |
Preclinical study of CLDN18.2 targeting antibody-drug conjugate for gastric cancer treatment |
| Drug-conjugate |
Gastric cancer, Gastroesophageal junction edema cancer |
CLDN18.2 |
Preclinical |
AbTis Co., Ltd. |
RS-2023-00219493 |
|
| 2 |
Development of a new class of PSMA target radiopharmaceuticals for prostate cancer |
| Drug-conjugate |
Castration-resistant prostate cancer |
PSMA |
Phase 2 |
FutureChem Co., Ltd. |
RS-2023-00218051 |
|
| 3 |
Derivation of lead substance for colorectal cancer treatment of Repebody-drug conjugate with EGFR overexpression tumor-specific selective effect |
| Drug-conjugate |
Solid Tumor (EGFR overexpression) |
EGFR |
Lead |
ProEn Therapeutics |
RS-2022-00166310 |
|
| 4 |
A study on the leading optimization for cancer immunotherapy of regulatory T cell suppression/depletion mechanism using CD25-ApDC (CD25 aptamer-drug-conjugate) |
| Drug-conjugate |
Solid Tumor |
CD25 |
Lead |
APTAMER Sciences |
RS-2022-00166270 |
|
| 5 |
Development of macrophage-targeted clodronate-glycosylated albumin complex
to inhibit tumor growth |
| Drug-conjugate |
Malignant tumor |
Macrophage |
Hit |
Seoul National University |
HN22C0644 |
|
| 6 |
Development of an implantable anticancer drug for prevention of local tumor recurrence and eradication of existing metastases after tumor resection of triple-negative breast cancer(TNBC) |
| Drug-conjugate |
TNBC |
Nucleolin |
Lead |
Interoligo |
HN22C0585 |
|
| 7 |
Development of ALCAM aptamer-based ApDC anticancer drug |
| Drug-conjugate |
Ovary cancer |
ALCAM |
Hit |
HiCELL Tech |
HN22C0558 |
|
| 8 |
Preclinical development of ITC-6146RO, a B7-H3 targeting ADC, for the Treatment of Non-Small Cell Lung Cancer |
| Drug-conjugate |
NSCLC |
B7-H3 |
Preclinical |
IntoCell |
HN22C0373 |
|
| 9 |
Clinical development of PSMA target therapeutic radiopharmaceutical for prostate cancer |
| Drug-conjugate |
Prostate cancer |
PSMA |
Phase 1 |
FutureChem. Co., Ltd. |
HN21C1297 |
|
| 10 |
Production of non-clinical and clinical samples of TROP2-ADC for IND filing and approval, or technology transfer |
| Drug-conjugate |
Solid Tumor |
TROP2 |
Preclinical |
LegoChem Biosciences, Inc. |
HN21C1199 |
|
| 11 |
Lead Generation of DLL3-ADC for the Treatment of Small Cell Lung Cancer |
| Drug-conjugate |
Rare cancer |
DLL3 |
Lead |
IntoCell |
HN21C1082 |
|
| 12 |
NN3201, an IND-enabling study stage multimodal, cKIT-targeting ADC for SCLC, GIST, and AML |
| Drug-conjugate |
Gastrointestinal stromal tumor |
C-kit, microtuble inhibition에 의한 cell cycle arrest, apoptosis 유도 |
Preclinical |
Novelty Nobility Inc. |
HN21C0860 |
|
| 13 |
Development of a novel ADC for the treatment of glioblastoma |
| Drug-conjugate |
Glioblastoma |
FGFR3 |
Candidate |
Aimed Bio Inc. |
HN21C0803 |
|
| 14 |
Development of Novel Radiopharmaceutical for Prostate Specific Membrane Antigen Targeted Therapy |
| Drug-conjugate |
Prostate cancer |
PSMA |
Phase 2 |
CellBion Co., Ltd. |
HN21C0626 |
|
| 15 |
Hit and lead compound discovery of antibody-drug conjugate (ADC) targeting Doppel, a tumor-specific molecule |
| Drug-conjugate |
Cancer |
Doppel |
Hit |
Seoul National University |
HN21C0264 |
|
